Precision Biologics is a pioneering company in the biotherapeutics and diagnostics sector, dedicated to improving the lives of cancer patients through innovative products. The company specializes in developing targeted monoclonal antibodies designed to attack tumors without harming healthy cells. Operating primarily in the oncology market, Precision Biologics serves healthcare providers and research institutions focused on cancer treatment and diagnostics. The business model revolves around the development and clinical trials of its proprietary antibodies, which are then licensed to pharmaceutical companies or sold directly to healthcare providers. Revenue is generated through licensing fees, sales of therapeutic products, and partnerships with other biotech firms. The company is currently advancing its first monoclonal antibody, NEO 102, through Phase 1 and 2 clinical trials for pancreatic and colorectal cancer.

Keywords: biotherapeutics, diagnostics, monoclonal antibodies, cancer treatment, oncology, clinical trials, NEO 102, targeted therapy, healthcare providers, biotechnology.